WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.
Jefferies Global Healthcare Conference 2025:
On Thursday, June 5, 2025, at 3:10 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat.
Goldman Sachs 46th Annual Global Healthcare Conference:
On Wednesday, June 11, 2025, at 9:20 a.m. ET, Kris, Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat.
Live webcasts of the fireside chats can be accessed on the Company’s website under Events and Presentations. The recordings will be archived and available on the Company’s website for 90 days.
About Prelude Therapeutics
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective SMARCA2 and KAT6A degraders, and ongoing research into other precision oncology targets. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. Our corporate presentation can be found at Events & Presentations - Prelude Therapeutics. For more information, visit preludetx.com.
Investor Contact:
Robert Doody
Senior Vice President, Investor Relations
Prelude Therapeutics
484.639.7235
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.11 |
| Daily Change: | -0.02 -1.77 |
| Daily Volume: | 71,434 |
| Market Cap: | US$48.560M |
August 14, 2025 May 06, 2025 March 10, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
